Seaport Therapeutics, Inc. Stock-Based Compensation
Seaport Therapeutics, Inc. (SPTX) reported Stock-Based Compensation of $36.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-03
- Seaport Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $36.86M, a 1999.26% increase year-over-year.
- Seaport Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.57M, a 58.68% increase year-over-year.
- Seaport Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $1.76M.
- Seaport Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $1.62M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month |
|---|---|---|
| 2026-06-30 | $36.86M 10-Q · filed 2026-08-03 | $39.43M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $2.57M 10-Q · filed 2026-06-08 | |
| 2025-06-30 | $1.76M 10-Q · filed 2026-08-03 | $3.38M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $1.62M 10-Q · filed 2026-06-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |